Xi-Hang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xi-Hang Chen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Chang Lin
The First Affiliated Hospital of Fujian Medical University
2 shared publicationsRong Zhang
The First Affiliated Hospital of Fujian Medical University
2 shared publications- Chaojun Zeng
Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China, Department of Otorhinolaryngology, Head and Neck Surgery, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital, Fujian Medical University, Fuzhou, China, Fujian Branch of National Clinical Medical Research Center for Otorhinolaryngologic Diseases, Fuzhou, China
1 shared publication Hongdong Liu
Department of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Chinese PLA Medical School
1 shared publicationJin-Mei Cheng
Department of Otorhinolaryngology Head and Neck Surgery, First Affiliated Hospital of Fujian Medical University, Taijiang District, Fuzhou, China
1 shared publicationShengnan Ye
The First Affiliated Hospital of Fujian Medical University
1 shared publication
Latest Publications
- Open Access
- 3 May 2025
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 145 (7) , 571-579
Cochlear inflammation in AAV-mediated gene therapy: serotype-dependent macrophage activation and promoter-driven immunogenicity
Recent clinical trials employing AAV (adeno-associated virus)-mediated gene therapy for hereditary deafness have demonstrated significant therapeutic potential. However, immune responses triggered by AAV delivery in the inner ear remain poorly characterized, despite their critical implications for treatment safety and efficacy. This study systematically evaluates serotype-specific (AAV1 vs. AAV9) and promoter-dependent (CMV vs CBA) immune responses in murine cochleae following local AAV delivery. Recombinant AAV1/AAV9 vectors expressing tdTomato under CMV or CBA promoters were injected via the posterior semicircular canal. Macrophage infiltration (F4/80+/CD68+ cells) was tracked for five weeks via immunohistochemistry. Temporal analysis revealed inflammation onset at one week, peaking at two weeks, and resolving to baseline by five weeks. CMV-driven vectors provoked significantly stronger immune activation than CBA. Serotype comparisons showed AAV9 induced greater immunogenicity, with elevated F4/80+ cells at two weeks (p < .001) and prolonged CD68+ cell elevation through four weeks (p < .001) versus AAV1. AAV9 triggered diffuse inflammation, while AAV1 responses were modiolus-restricted. These findings highlight serotype- and promoter-dependent immunogenicity as key determinants of cochlear inflammation. Strategic selection of AAV components is essential to balance transduction efficiency and immune tolerance in inner ear gene therapy.
- 3 May 2025
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 145 (7) , 571-579
Open AccessCochlear inflammation in AAV-mediated gene therapy: serotype-dependent macrophage activation and promoter-driven immunogenicity
Recent clinical trials employing AAV (adeno-associated virus)-mediated gene therapy for hereditary deafness have demonstrated significant therapeutic potential. However, immune responses triggered by AAV delivery in the inner ear remain poorly characterized, despite their critical implications for treatment safety and efficacy. This study systematically evaluates serotype-specific (AAV1 vs. AAV9) and promoter-dependent (CMV vs CBA) immune responses in murine cochleae following local AAV delivery. Recombinant AAV1/AAV9 vectors expressing tdTomato under CMV or CBA promoters were injected via the posterior semicircular canal. Macrophage infiltration (F4/80+/CD68+ cells) was tracked for five weeks via immunohistochemistry. Temporal analysis revealed inflammation onset at one week, peaking at two weeks, and resolving to baseline by five weeks. CMV-driven vectors provoked significantly stronger immune activation than CBA. Serotype comparisons showed AAV9 induced greater immunogenicity, with elevated F4/80+ cells at two weeks (p < .001) and prolonged CD68+ cell elevation through four weeks (p < .001) versus AAV1. AAV9 triggered diffuse inflammation, while AAV1 responses were modiolus-restricted. These findings highlight serotype- and promoter-dependent immunogenicity as key determinants of cochlear inflammation. Strategic selection of AAV components is essential to balance transduction efficiency and immune tolerance in inner ear gene therapy.
- Open Access
- 31 January 2024
- Published by Wiley
The biofilm characteristics and management of skin flap infection following cochlear implantation: A prospective study from 2001 to 2021
Objective: To assess the clinical features and the management of skin flap infection (SFI) following cochlear implantation (CI) and to characterize the biofilm features by the scanning electron microscopy.Setting: The study was conducted at a tertiary care center.Participants: A total of 1,251 patients receiving CI in the First Affiliated Hospital of Fujian Medical University between August 2001 and March 2021 were enrolled. Scanning electron microscopy was utilized for characterizing the etiology of infection. Main outcome measures: A proposed stratification system was applied to optimize treatments for post-operation flap infection.Results: After CI, SFI was reported in 16 patients (1.28%) and patients under 18-year-old were more prone to flap infection. Staphylococcus Aureus was found to be the most common bacterial culprit for flap infection, with 6 cases explored in this group (6/16, 37.5%). Bacterial biofilm was observed within the jelly-like substance on the surface of CI equipment of SFI patients. A two-stage stratification was proposed for optimizing the treatment schemes. Conservative therapy was recommended for stage I cases while surgical treatment was the preferred method for stage II patients.Conclusions: Pediatric patients are more susceptible to SFI after CI. The formation of bacterial biofilm may be the vital cause of SFI. The proposed stratification can facilitate the management of SFI.
- 31 January 2024
- Published by Wiley
Open AccessThe biofilm characteristics and management of skin flap infection following cochlear implantation: A prospective study from 2001 to 2021
Objective: To assess the clinical features and the management of skin flap infection (SFI) following cochlear implantation (CI) and to characterize the biofilm features by the scanning electron microscopy.Setting: The study was conducted at a tertiary care center.Participants: A total of 1,251 patients receiving CI in the First Affiliated Hospital of Fujian Medical University between August 2001 and March 2021 were enrolled. Scanning electron microscopy was utilized for characterizing the etiology of infection. Main outcome measures: A proposed stratification system was applied to optimize treatments for post-operation flap infection.Results: After CI, SFI was reported in 16 patients (1.28%) and patients under 18-year-old were more prone to flap infection. Staphylococcus Aureus was found to be the most common bacterial culprit for flap infection, with 6 cases explored in this group (6/16, 37.5%). Bacterial biofilm was observed within the jelly-like substance on the surface of CI equipment of SFI patients. A two-stage stratification was proposed for optimizing the treatment schemes. Conservative therapy was recommended for stage I cases while surgical treatment was the preferred method for stage II patients.Conclusions: Pediatric patients are more susceptible to SFI after CI. The formation of bacterial biofilm may be the vital cause of SFI. The proposed stratification can facilitate the management of SFI.
- Open Access
- 26 March 2019
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 98 (5) , E13-E20
The Natural History of Labyrinthine Hemorrhage in Patients With Sudden Sensorineural Hearing Loss
To investigate the application of inner ear 3-dimensional fluid-attenuated inversion recovery (3D-FLAIR) magnetic resonance imaging (MRI) in patients with sudden sensorineural hearing loss (SSNHL) accompanied by inner ear hemorrhage. A total of 1252 SSNHL patients who were admitted from January 2010 to April 2018 were included in the study. The patients’ clinical features, complete blood counts, coagulation profiles, audiometry data, and MRI scans were retrospectively reviewed. Twenty-four patients had high labyrinth signals on inner ear 3D-FLAIR MRI (24/1252, 1.9%) that were diagnosed as inner ear hemorrhage. One patient had endolymphatic hydrops on the contralesional side. In the 24 patients, pure tone audiometry curves revealed profound deafness (19/24) and flat moderate hearing loss (5/24); most patients had associated vertigo (23/24) and tinnitus (19/24). Patients with SSNHL (N = 24) were treated. Sixteen patients had invalid improvement, 3 patients were markedly improved, 4 patients had effective treatment, and only 1 patient was cured, for a therapeutic efficacy of 33.3% (8/24). Follow-up 3D-FLAIR MRI in patients showed absorbance of labyrinthine hemorrhage and disappearance of the high signal intensity in the inner ear within 2 weeks to 4 months. Inner ear 3D-FLAIR MRI indicate that most cases of inner ear hemorrhage are spontaneous and that high labyrinth signals are absorbed within 4 months. The site of labyrinth hemorrhage is irregular and independent of hearing loss. Conventional treatment is not very effective, and an appropriate therapy for SSNHL requires further investigation.
- 26 March 2019
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 98 (5) , E13-E20
Open AccessThe Natural History of Labyrinthine Hemorrhage in Patients With Sudden Sensorineural Hearing Loss
To investigate the application of inner ear 3-dimensional fluid-attenuated inversion recovery (3D-FLAIR) magnetic resonance imaging (MRI) in patients with sudden sensorineural hearing loss (SSNHL) accompanied by inner ear hemorrhage. A total of 1252 SSNHL patients who were admitted from January 2010 to April 2018 were included in the study. The patients’ clinical features, complete blood counts, coagulation profiles, audiometry data, and MRI scans were retrospectively reviewed. Twenty-four patients had high labyrinth signals on inner ear 3D-FLAIR MRI (24/1252, 1.9%) that were diagnosed as inner ear hemorrhage. One patient had endolymphatic hydrops on the contralesional side. In the 24 patients, pure tone audiometry curves revealed profound deafness (19/24) and flat moderate hearing loss (5/24); most patients had associated vertigo (23/24) and tinnitus (19/24). Patients with SSNHL (N = 24) were treated. Sixteen patients had invalid improvement, 3 patients were markedly improved, 4 patients had effective treatment, and only 1 patient was cured, for a therapeutic efficacy of 33.3% (8/24). Follow-up 3D-FLAIR MRI in patients showed absorbance of labyrinthine hemorrhage and disappearance of the high signal intensity in the inner ear within 2 weeks to 4 months. Inner ear 3D-FLAIR MRI indicate that most cases of inner ear hemorrhage are spontaneous and that high labyrinth signals are absorbed within 4 months. The site of labyrinth hemorrhage is irregular and independent of hearing loss. Conventional treatment is not very effective, and an appropriate therapy for SSNHL requires further investigation.